COMP <GO>
CNMD vs JNJ // DIVIDEND YIELD & FCF PAYOUT SAFETY
CONMED Corporation (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CNMD 3
— JNJ 10
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: CNMD
LAST: $45.72 (-0.09%) • MKT CAP: $1.36B
dividend-safety
1.82%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CNMD VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CNMD | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.60% | 67.90% | -13.30 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.80% | 25.50% | -17.70 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.4x | 18.5x | -7.10 | CNMD | /valuation <GO> |
| Free Cash Flow Yield | 11.07% | 2.97% | +8.10 | CNMD | /fcf-yield <GO> |
| Operating Margin | 7.50% | 34.70% | -27.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 3.40% | 28.50% | -25.10 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 6.00% | -0.80 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 1.82% | 0.00% | +1.82 | CNMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.91 | 5.59 | -3.68 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.6 | 62.1 | -21.50 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.9x | 23.0x | +3.90 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.36B | $662.49B | -$661.13B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CNMD REV | JNJ REV | CNMD GROSS % | JNJ GROSS % | CNMD FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.37B | $94.19B | 54.6% | 67.9% | $150.9M | $19.70B |
| FY 2024 | $1.31B | $88.82B | 56.1% | 69.1% | $153.9M | $19.84B |
| FY 2023 | $1.24B | $85.16B | — | — | $125.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CNMD // BETA —
JNJ // BETA 1.08